Johnson & Johnson RYBREVANT Amivantamab NSCLC Regimen Delivers Longest Reported Survival in EGFR Exon 20 Lung Cancer
Final PAPILLON trial results show Johnson & Johnson’s RYBREVANT (amivantamab-vmjw) plus chemotherapy achieved a 34.3-month median overall survival in EGFR exon 20 insertion-positive NSCLC — the longest reported to date in this historically hard-to-treat population.
